Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL23AP25 (Ribosomal protein L23a pseudogene 25) is a processed pseudogene in the human genome and does not encode a functional ribosomal protein. It is one of many dispersed genomic sequences similar to the functional ribosomal protein L23a gene (RPL23A), which encodes a component of the large 60S ribosomal subunit[4][5]. Like other ribosomal protein pseudogenes, RPL23AP25 lacks coding potential due to mutations or truncations and typically does not produce protein. There is no evidence RPL23AP25 is involved in cellular signaling, disease mechanisms, drug interactions, or serves as a clinically relevant biomarker[4][5][7]. The approved gene symbol is RPL23AP25, and it is cataloged as a pseudogene by the HUGO Gene Nomenclature Committee[4]. If you intended to refer to the functional ribosomal protein L23a (RPL23A) rather than this pseudogene, please clarify, as RPL23A itself can be relevant to ribosome biology and has related disease associations[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 25 (RPL23AP25).